IVD Technology

Geneoscopy, a healthcare company, has announced the commercial launch of Colosense, a groundbreaking at-home colorectal cancer screening test. This innovative, noninvasive test comes on the heels of an impressive $105 million funding round and FDA approval, positioning Colosense as a major player

Personalized medicine through IVD (In Vitro Diagnostics) represents a transformative shift in healthcare, focusing on tailored medical treatment based on individual patient profiles. This innovative approach is reshaping how diseases are diagnosed, monitored, and treated, promising improved

The FDA's recent approval of Illumina's TruSight Oncology (TSO) Comprehensive, an in vitro diagnostic (IVD) biomarker test kit, represents a notable milestone in cancer treatment. This approval paves the way for more personalized and precise therapy options for cancer patients. By

The in vitro diagnostic (IVD) medical device market is on the cusp of transformative growth, driven by technological advancements, increased prevalence of chronic diseases, and a growing demand for early and accurate diagnostics. IVD devices, including reagents, test kits, and laboratory equipment,

The in vitro diagnostics (IVD) raw materials market is set to experience remarkable growth over the next decade, driven by technological advancements and increasing demands in healthcare. As the world's health needs evolve, this market, valued at USD 14,560 million in 2023, is anticipated to

The Transitional Coverage for Emerging Technologies (TCET) Medicare payment pathway, detailed in a recent final notice by the Centers for Medicare & Medicaid Services (CMS), promises to revolutionize the way breakthrough medical technologies receive coverage and reimbursement under Medicare.